vs

Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and NexPoint Real Estate Finance, Inc. (NREF). Click either name above to swap in a different company.

ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $11.1M, roughly 1.7× NexPoint Real Estate Finance, Inc.). NexPoint Real Estate Finance, Inc. runs the higher net margin — 216.6% vs -64.1%, a 280.8% gap on every dollar of revenue. On growth, ENANTA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.8% vs -48.8%).

Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.

NexPoint Real Estate Finance, Inc. is a US-based commercial real estate finance firm that offers structured financing solutions for multifamily, office, industrial, and hospitality properties. It focuses on originating, managing and servicing a diversified portfolio of mortgage loans and real estate-related investments to deliver stable risk-adjusted returns to stakeholders.

ENTA vs NREF — Head-to-Head

Bigger by revenue
ENTA
ENTA
1.7× larger
ENTA
$18.6M
$11.1M
NREF
Growing faster (revenue YoY)
ENTA
ENTA
+58.6% gap
ENTA
9.8%
-48.8%
NREF
Higher net margin
NREF
NREF
280.8% more per $
NREF
216.6%
-64.1%
ENTA

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ENTA
ENTA
NREF
NREF
Revenue
$18.6M
$11.1M
Net Profit
$-11.9M
$24.0M
Gross Margin
Operating Margin
-60.5%
Net Margin
-64.1%
216.6%
Revenue YoY
9.8%
-48.8%
Net Profit YoY
46.4%
58.7%
EPS (diluted)
$-0.42
$0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ENTA
ENTA
NREF
NREF
Q4 25
$18.6M
$11.1M
Q3 25
$15.1M
$12.5M
Q2 25
$18.3M
$12.1M
Q1 25
$14.9M
$11.5M
Q4 24
$17.0M
$21.7M
Q3 24
$14.6M
$12.5M
Q2 24
$18.0M
$6.7M
Q1 24
$17.1M
$-12.8M
Net Profit
ENTA
ENTA
NREF
NREF
Q4 25
$-11.9M
$24.0M
Q3 25
$-18.7M
$50.9M
Q2 25
$-18.3M
$22.3M
Q1 25
$-22.6M
$26.0M
Q4 24
$-22.3M
$15.2M
Q3 24
$-28.8M
$23.3M
Q2 24
$-22.7M
$12.1M
Q1 24
$-31.2M
$-14.6M
Operating Margin
ENTA
ENTA
NREF
NREF
Q4 25
-60.5%
Q3 25
-121.6%
Q2 25
-103.2%
Q1 25
-164.3%
Q4 24
-138.8%
Q3 24
-204.4%
Q2 24
-134.6%
Q1 24
-192.1%
Net Margin
ENTA
ENTA
NREF
NREF
Q4 25
-64.1%
216.6%
Q3 25
-123.6%
407.0%
Q2 25
-99.7%
184.5%
Q1 25
-151.7%
225.6%
Q4 24
-131.4%
69.9%
Q3 24
-197.3%
186.4%
Q2 24
-126.1%
179.7%
Q1 24
-182.7%
114.3%
EPS (diluted)
ENTA
ENTA
NREF
NREF
Q4 25
$-0.42
$0.47
Q3 25
$-0.88
$1.14
Q2 25
$-0.85
$0.54
Q1 25
$-1.06
$0.70
Q4 24
$-1.05
$0.71
Q3 24
$-1.36
$0.74
Q2 24
$-1.07
$0.40
Q1 24
$-1.47
$-0.83

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ENTA
ENTA
NREF
NREF
Cash + ST InvestmentsLiquidity on hand
$37.4M
$31.1M
Total DebtLower is stronger
$771.2M
Stockholders' EquityBook value
$126.6M
$388.0M
Total Assets
$329.5M
$5.3B
Debt / EquityLower = less leverage
1.99×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ENTA
ENTA
NREF
NREF
Q4 25
$37.4M
$31.1M
Q3 25
$32.3M
$17.9M
Q2 25
$44.8M
$9.1M
Q1 25
$60.2M
$19.2M
Q4 24
$84.3M
$3.9M
Q3 24
$37.2M
$34.7M
Q2 24
$35.8M
$4.3M
Q1 24
$63.5M
$13.5M
Total Debt
ENTA
ENTA
NREF
NREF
Q4 25
$771.2M
Q3 25
$720.9M
Q2 25
$815.6M
Q1 25
$831.5M
Q4 24
$799.3M
Q3 24
$815.5M
Q2 24
$861.0M
Q1 24
$843.3M
Stockholders' Equity
ENTA
ENTA
NREF
NREF
Q4 25
$126.6M
$388.0M
Q3 25
$64.7M
$375.4M
Q2 25
$79.3M
$348.2M
Q1 25
$93.5M
$343.7M
Q4 24
$111.8M
$336.5M
Q3 24
$128.8M
$335.8M
Q2 24
$148.9M
$327.5M
Q1 24
$166.1M
$327.1M
Total Assets
ENTA
ENTA
NREF
NREF
Q4 25
$329.5M
$5.3B
Q3 25
$280.7M
$5.3B
Q2 25
$301.0M
$5.4B
Q1 25
$323.0M
$5.4B
Q4 24
$348.6M
$5.4B
Q3 24
$376.7M
$5.7B
Q2 24
$398.8M
$6.6B
Q1 24
$413.6M
$7.1B
Debt / Equity
ENTA
ENTA
NREF
NREF
Q4 25
1.99×
Q3 25
1.92×
Q2 25
2.34×
Q1 25
2.42×
Q4 24
2.38×
Q3 24
2.43×
Q2 24
2.63×
Q1 24
2.58×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ENTA
ENTA
NREF
NREF
Operating Cash FlowLast quarter
$-11.7M
$-4.5M
Free Cash FlowOCF − Capex
$-11.8M
FCF MarginFCF / Revenue
-63.6%
Capex IntensityCapex / Revenue
0.8%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$-18.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ENTA
ENTA
NREF
NREF
Q4 25
$-11.7M
$-4.5M
Q3 25
$-6.5M
$8.1M
Q2 25
$17.5M
$3.3M
Q1 25
$-13.5M
$16.0M
Q4 24
$-16.8M
$4.4M
Q3 24
$-10.4M
$14.7M
Q2 24
$-14.8M
$-7.5M
Q1 24
$-28.6M
$17.7M
Free Cash Flow
ENTA
ENTA
NREF
NREF
Q4 25
$-11.8M
Q3 25
$-7.9M
Q2 25
$17.4M
Q1 25
$-16.0M
Q4 24
$-25.5M
Q3 24
$-19.4M
Q2 24
$-21.3M
Q1 24
$-30.3M
FCF Margin
ENTA
ENTA
NREF
NREF
Q4 25
-63.6%
Q3 25
-52.5%
Q2 25
94.7%
Q1 25
-107.4%
Q4 24
-150.6%
Q3 24
-132.5%
Q2 24
-118.6%
Q1 24
-177.5%
Capex Intensity
ENTA
ENTA
NREF
NREF
Q4 25
0.8%
Q3 25
9.6%
Q2 25
0.8%
Q1 25
17.0%
Q4 24
51.6%
Q3 24
61.3%
Q2 24
36.4%
Q1 24
9.8%
Cash Conversion
ENTA
ENTA
NREF
NREF
Q4 25
-0.19×
Q3 25
0.16×
Q2 25
0.15×
Q1 25
0.62×
Q4 24
0.29×
Q3 24
0.63×
Q2 24
-0.62×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons